# Influence of High Myopia on Outcomes of iStent Inject W Implantation Combined with Cataract Surgery up to 24 Months of Follow-Up

**Authors:** Yuto Shiotani, Takeshi Yoshida, Sota Yoshimoto, Keigo Sugisawa, Shintaro Yasuda, Motohisa Ohno, Ryu Teramatsu, Hiroki Iemura, Yusaku Shibata, Kyoko Ohno-Matsui

PMC · DOI: 10.3390/jcm15031265 · Journal of Clinical Medicine · 2026-02-05

## TL;DR

This study found that iStent implantation combined with cataract surgery is less effective at lowering eye pressure in patients with high myopia compared to those without.

## Contribution

The study provides new evidence on the limited efficacy of iStent inject W in high myopia patients up to 24 months post-surgery.

## Key findings

- Non-high myopia eyes showed significant IOP reduction at all postoperative time points.
- High myopia eyes had significantly lower surgical success rates (19.4%) compared to non-high myopia eyes (48.6%) at 24 months.
- Both groups experienced a significant decrease in glaucoma medications from baseline to 24 months.

## Abstract

Background: The purpose of this study was to evaluate the 2-year postoperative outcomes of iStent inject W implantation combined with phacoemulsification, with a specific focus on comparing results between high myopia (HM) and non-high myopia (non-HM) eyes. Methods: In this retrospective study, subjects were divided into HM and non-HM groups using an axial length cut-off of 26.0 mm. The main outcome measures were intraocular pressure (IOP), number of glaucoma medications, surgical success rates, and postoperative complications. Surgical success was defined as a decrease in glaucoma medical therapy of ≥1 medication without an increase in IOP, or a postoperative IOP ≤ 21 mmHg with a ≥20% reduction. Changes from baseline were analyzed up to 24 months postoperatively. Results: The non-HM group achieved a significant IOP reduction at all postoperative time points. The HM group showed no significant postoperative IOP reduction except at 3 months. The mean number of medications significantly decreased from baseline to 24 months in two groups. The cumulative surgical success rate at 24 months was 48.6% in the non-HM group, whereas it was significantly lower at 19.4% in the HM group (p = 0.038). No significant difference in the incidence of postoperative complications was observed between the groups. Conclusions: The IOP-lowering efficacy of iStent inject W implantation combined with phacoemulsification appeared limited in eyes with HM. These results may suggest the need for careful patient selection and clinical judgment when considering iStent inject W implantation in this population.

## Linked entities

- **Diseases:** glaucoma (MONDO:0005041)

## Full-text entities

- **Diseases:** glaucoma (MESH:D005901), HM (MESH:D009216)
- **Chemicals:** W (MESH:D014414)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12897585/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12897585/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12897585/full.md

---
Source: https://tomesphere.com/paper/PMC12897585